The University of Tokyo is the first national university corporation to obtain a manufacturing site registration and manufacturing license for products used in regenerative medicine.Cells prepared from the umbilical cord at the Institute of Medical Science are manufactured as products for regenerative medicine.
According to the Institute of Medical Science, the University of Tokyo, the IMSUT-HLC cell processing facility at the Institute of Medical Science was registered as a manufacturing facility.It will be established in 2021 under a joint research agreement with drug development company Human Life Code.
It manufactures cells prepared from the umbilical cord, the string-like tissue that connects the baby in the womb to the mother.The hematopoietic stem cells and immune cells in the cord blood remaining in the umbilical cord are known to be useful in various medical treatments. It is also expected to be applied to regenerative medicine.
It is characterized by being able to increase this in large quantities and administer it to unrelated people.The Umbilical Cord Blood and Umbilical Cord Bank of the Institute of Medical Science, The University of Tokyo utilizes umbilical cords collected with the consent of mothers at obstetrics and gynecology departments nationwide, promotes development research, and produces cells that will be used as raw materials for treatments.
